US20040127502A1 - Use of GAL3 antagonist for treatment of depression - Google Patents

Use of GAL3 antagonist for treatment of depression Download PDF

Info

Publication number
US20040127502A1
US20040127502A1 US10/723,961 US72396103A US2004127502A1 US 20040127502 A1 US20040127502 A1 US 20040127502A1 US 72396103 A US72396103 A US 72396103A US 2004127502 A1 US2004127502 A1 US 2004127502A1
Authority
US
United States
Prior art keywords
branched
straight chained
alkyl
aryl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/723,961
Other languages
English (en)
Inventor
Thomas Blackburn
Michael Konkel
Lakmal Boteju
Ian Talisman
John Wetzel
Mathivana Packiarajan
Heidi Chen
Hermo Jimenez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
Synaptic Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/066,175 external-priority patent/US20030078271A1/en
Application filed by Synaptic Pharmaceutical Corp filed Critical Synaptic Pharmaceutical Corp
Priority to US10/723,961 priority Critical patent/US20040127502A1/en
Publication of US20040127502A1 publication Critical patent/US20040127502A1/en
Assigned to H. LUNDBECK A/S reassignment H. LUNDBECK A/S ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SYNAPTIC PHARMACEUTICAL CORPORATION
Priority to US11/517,589 priority patent/US7465750B2/en
Priority to US12/314,675 priority patent/US20090318504A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US10/723,961 2001-01-31 2003-11-26 Use of GAL3 antagonist for treatment of depression Abandoned US20040127502A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/723,961 US20040127502A1 (en) 2001-01-31 2003-11-26 Use of GAL3 antagonist for treatment of depression
US11/517,589 US7465750B2 (en) 2001-01-31 2006-09-06 Use of GAL3 antagonist for treatment of depression and/or anxiety and compounds useful in such methods
US12/314,675 US20090318504A1 (en) 2001-01-31 2008-12-15 Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26558601P 2001-01-31 2001-01-31
US10/066,175 US20030078271A1 (en) 2001-01-31 2002-01-31 Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
US10/723,961 US20040127502A1 (en) 2001-01-31 2003-11-26 Use of GAL3 antagonist for treatment of depression

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/066,175 Continuation US20030078271A1 (en) 2001-01-31 2002-01-31 Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/517,589 Continuation US7465750B2 (en) 2001-01-31 2006-09-06 Use of GAL3 antagonist for treatment of depression and/or anxiety and compounds useful in such methods

Publications (1)

Publication Number Publication Date
US20040127502A1 true US20040127502A1 (en) 2004-07-01

Family

ID=32658730

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/723,961 Abandoned US20040127502A1 (en) 2001-01-31 2003-11-26 Use of GAL3 antagonist for treatment of depression
US11/517,589 Expired - Fee Related US7465750B2 (en) 2001-01-31 2006-09-06 Use of GAL3 antagonist for treatment of depression and/or anxiety and compounds useful in such methods
US12/314,675 Abandoned US20090318504A1 (en) 2001-01-31 2008-12-15 Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods

Family Applications After (2)

Application Number Title Priority Date Filing Date
US11/517,589 Expired - Fee Related US7465750B2 (en) 2001-01-31 2006-09-06 Use of GAL3 antagonist for treatment of depression and/or anxiety and compounds useful in such methods
US12/314,675 Abandoned US20090318504A1 (en) 2001-01-31 2008-12-15 Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods

Country Status (1)

Country Link
US (3) US20040127502A1 (US07465750-20081216-C00215.png)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030178369A1 (en) * 2000-08-10 2003-09-25 Tamiyuki Eguchi Immersion type membrane filter
US20040082587A1 (en) * 2002-08-07 2004-04-29 Mathivanan Packiarajan 2,4,6-Triaminopyrimidines for the treatment of depression and/or anxiety
US20040092570A1 (en) * 2002-08-07 2004-05-13 Blackburn Thomas P. GAL3 antagonists for the treatment of neuropathic pain
US20040110821A1 (en) * 2002-08-07 2004-06-10 Konkel Michael J. GAL3 receptor antagonists for the treatment of affective disorders
US20050148635A1 (en) * 2002-08-07 2005-07-07 Michael Konkel 3-imino-2-indolones for the treatment of depression and/or anxiety
US7081470B2 (en) 2001-01-31 2006-07-25 H. Lundbeck A/S Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
US20060172989A1 (en) * 2005-02-02 2006-08-03 Michael Konkel Aminoalkoxyphenyl indolone derivatives
WO2007118899A1 (en) * 2006-04-19 2007-10-25 Abbott Gmbh & Co. Kg Heterocyclic arylsulphones suitable for treating disorders that respond to modulation of the serotonin 5ht6 receptor
EP1956006A1 (en) * 2007-02-06 2008-08-13 Laboratorios del Dr. Esteve S.A. Heterocyclyl-substituted-tetrahydro-naphthalen derivatives as 5-HT7 receptor ligands
EP1975161A1 (en) * 2007-03-28 2008-10-01 Laboratorios del Dr. Esteve S.A. Heterocyclyl-substituted- tetrahydro-napthalen-amine derivatives, their preparation and use as medicaments

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127502A1 (en) * 2001-01-31 2004-07-01 Synaptic Pharmaceutical Corporation Use of GAL3 antagonist for treatment of depression
US7642281B2 (en) * 2002-08-07 2010-01-05 Helicon Therapeutics, Inc. Indolone compounds useful to treat cognitive impairment
US20070135509A1 (en) * 2005-12-09 2007-06-14 Blackburn Thomas P Indolone compounds useful to treat cognitive impairment

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4874687A (en) * 1986-11-18 1989-10-17 Fuji Photo Film Co., Ltd. Method for forming an image
US4921503A (en) * 1988-09-12 1990-05-01 Clairol Incorporated Novel dyeing system
US4946956A (en) * 1988-09-21 1990-08-07 Uniroyal Chemical Company, Inc. Arylenediamine substituted pyrimidines
US5017466A (en) * 1989-05-24 1991-05-21 Fuji Photo Film Co., Ltd. Color-forming aminopyrimidine couplers and silver halide color photographic light-sensitive materials containing the coupler
US5547949A (en) * 1992-06-09 1996-08-20 Richter Gedeon Vegyeszeti Gyar Rt. Steroids with pregnane skeleton, pharmaceutical compositions containing them
US5728704A (en) * 1992-09-28 1998-03-17 Pfizer Inc. Substituted pyridmidines for control of diabetic complications
US5801150A (en) * 1993-06-23 1998-09-01 Caillot; Jean-Luc Aminopyri(mi)dine derivatives combined with amino acids, and pharmacological activities thereof
US5840893A (en) * 1995-01-06 1998-11-24 The Picower Institute For Medical Research Compounds for treating infectious diseases
US5921503A (en) * 1998-02-04 1999-07-13 Tsay; Ing-Lang Assistant landing device of a troubled airplane
US6287788B1 (en) * 1996-10-09 2001-09-11 Synaptic Pharmaceutical Corporation DNA encoding galanin GALR3 receptors and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1477349A (en) 1975-09-24 1977-06-22 Ciba Geigy Ag Azo pigments
US5198461A (en) 1989-12-11 1993-03-30 Neurosearch A/S Isatine derivatives, their preparation and use
JP3374136B2 (ja) 1991-11-12 2003-02-04 三洋電機株式会社 リチウム二次電池
HUT64323A (en) 1992-06-09 1993-12-28 Richter Gedeon Vegyeszet Process for production new piperazinyl-bis(alkyl-amino)-pyrimidine derivatives
DE69408750T2 (de) 1993-08-26 1998-07-23 Ono Pharmaceutical Co 4-Aminopyrimidin Derivate
US5565580A (en) 1994-01-27 1996-10-15 Neurosearch A/S Glutamate Antagonists
EP0788890A1 (en) 1996-02-06 1997-08-13 Agfa-Gevaert N.V. Dyes and dye-donor elements for thermal dye transfer recording
JP3319960B2 (ja) * 1996-10-17 2002-09-03 富士通株式会社 半導体装置
JPH11158073A (ja) 1997-09-26 1999-06-15 Takeda Chem Ind Ltd アデノシンａ３拮抗剤
ATE245641T1 (de) 1998-02-17 2003-08-15 Tularik Inc Antivirale pyrimidinderivate
ATE232521T1 (de) 1998-03-27 2003-02-15 Janssen Pharmaceutica Nv Hiv hemmende pyrimidin derivate
EP0945442A1 (en) 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted pyrimidine derivatives
AU4685799A (en) 1998-06-17 2000-01-05 Geron Corporation Telomerase inhibitors
AU740813B2 (en) 1998-07-08 2001-11-15 Monash University Pharmaceutical agents
EP0972770B1 (en) 1998-07-14 2001-09-19 Basf Aktiengesellschaft Acaricidal and insecticidal substituted pyrimidines and a process for the preparation thereof
US20040127502A1 (en) * 2001-01-31 2004-07-01 Synaptic Pharmaceutical Corporation Use of GAL3 antagonist for treatment of depression
US7081470B2 (en) * 2001-01-31 2006-07-25 H. Lundbeck A/S Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
US6996172B2 (en) 2001-12-21 2006-02-07 Motorola, Inc. Method and structure for scalability type selection in digital video
US20040082615A1 (en) * 2002-08-07 2004-04-29 Michael Konkel 3-Imino-2-indolones for the treatement of depression and/or anxiety
US7220775B2 (en) * 2002-08-07 2007-05-22 H. Lundbeck A/S Compound useful for the treatment of neuropathic pain

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4874687A (en) * 1986-11-18 1989-10-17 Fuji Photo Film Co., Ltd. Method for forming an image
US4921503A (en) * 1988-09-12 1990-05-01 Clairol Incorporated Novel dyeing system
US4946956A (en) * 1988-09-21 1990-08-07 Uniroyal Chemical Company, Inc. Arylenediamine substituted pyrimidines
US5017466A (en) * 1989-05-24 1991-05-21 Fuji Photo Film Co., Ltd. Color-forming aminopyrimidine couplers and silver halide color photographic light-sensitive materials containing the coupler
US5547949A (en) * 1992-06-09 1996-08-20 Richter Gedeon Vegyeszeti Gyar Rt. Steroids with pregnane skeleton, pharmaceutical compositions containing them
US5728704A (en) * 1992-09-28 1998-03-17 Pfizer Inc. Substituted pyridmidines for control of diabetic complications
US5801150A (en) * 1993-06-23 1998-09-01 Caillot; Jean-Luc Aminopyri(mi)dine derivatives combined with amino acids, and pharmacological activities thereof
US5840893A (en) * 1995-01-06 1998-11-24 The Picower Institute For Medical Research Compounds for treating infectious diseases
US6287788B1 (en) * 1996-10-09 2001-09-11 Synaptic Pharmaceutical Corporation DNA encoding galanin GALR3 receptors and uses thereof
US6329197B2 (en) * 1996-10-09 2001-12-11 Synaptic Pharmaceutical Corporation DNA encoding galanin GALR3 receptors and uses thereof
US6368812B1 (en) * 1996-10-09 2002-04-09 Synaptic Pharmaceutical Corporation Process for determining the agonist or antagonist of galanin receptor (GALR3)
US5921503A (en) * 1998-02-04 1999-07-13 Tsay; Ing-Lang Assistant landing device of a troubled airplane

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030178369A1 (en) * 2000-08-10 2003-09-25 Tamiyuki Eguchi Immersion type membrane filter
US7868034B2 (en) 2001-01-31 2011-01-11 H. Lundbeck A/S Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
US20090176840A1 (en) * 2001-01-31 2009-07-09 Michael Konkel Use of galr3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
US7081470B2 (en) 2001-01-31 2006-07-25 H. Lundbeck A/S Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
US6936607B2 (en) 2002-08-07 2005-08-30 H. Lunobeck A/S 2,4,6-Triaminopyrimidines for the treatment of depression and/or anxiety
US20040092570A1 (en) * 2002-08-07 2004-05-13 Blackburn Thomas P. GAL3 antagonists for the treatment of neuropathic pain
US20040110821A1 (en) * 2002-08-07 2004-06-10 Konkel Michael J. GAL3 receptor antagonists for the treatment of affective disorders
US7166635B2 (en) 2002-08-07 2007-01-23 H. Lundbeck A/S 3-imino-2-indolones for the treatment of depression and/or anxiety
US20040082587A1 (en) * 2002-08-07 2004-04-29 Mathivanan Packiarajan 2,4,6-Triaminopyrimidines for the treatment of depression and/or anxiety
US20050148635A1 (en) * 2002-08-07 2005-07-07 Michael Konkel 3-imino-2-indolones for the treatment of depression and/or anxiety
US20060172989A1 (en) * 2005-02-02 2006-08-03 Michael Konkel Aminoalkoxyphenyl indolone derivatives
WO2007118899A1 (en) * 2006-04-19 2007-10-25 Abbott Gmbh & Co. Kg Heterocyclic arylsulphones suitable for treating disorders that respond to modulation of the serotonin 5ht6 receptor
US8642642B2 (en) 2006-04-19 2014-02-04 Abbott Laboratories Heterocyclic arylsulphones suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor
US20090306175A1 (en) * 2006-04-19 2009-12-10 Abbott Gmbh & Co. Kg Heterocyclic arylsulphones suitable for treating disorders that respond to modulation of the serotonin 5ht6 receptor
US20100035936A1 (en) * 2007-02-06 2010-02-11 Laboratorios Del Dr. Esteve, S.A. Heterocyclyl substituted tetrahydronaphthalene derivatives as 5-ht7 receptor ligands
WO2008095689A1 (en) * 2007-02-06 2008-08-14 Laboratorios Del Dr. Esteve, S.A. Heterocyclyl substituted tetrahydronaphthalene derivatives as 5-ht7 receptor ligands
US8097641B2 (en) 2007-02-06 2012-01-17 Laboratorios Del Dr. Esteve, S.A. Heterocyclyl substituted tetrahydronaphthalene derivatives as 5-HT7 receptor ligands
EP1956006A1 (en) * 2007-02-06 2008-08-13 Laboratorios del Dr. Esteve S.A. Heterocyclyl-substituted-tetrahydro-naphthalen derivatives as 5-HT7 receptor ligands
WO2008116663A3 (en) * 2007-03-28 2008-11-06 Esteve Labor Dr Heterocyclyl-substituted-tetrahydro-naphthalen-amine derivatives, their preparation and use as medicaments
WO2008116663A2 (en) * 2007-03-28 2008-10-02 Laboratorios Del Dr. Esteve, S.A. Heterocyclyl-substituted-tetrahydro-naphthalen-amine derivatives, their preparation and use as medicaments
EP1975161A1 (en) * 2007-03-28 2008-10-01 Laboratorios del Dr. Esteve S.A. Heterocyclyl-substituted- tetrahydro-napthalen-amine derivatives, their preparation and use as medicaments
US20100105684A1 (en) * 2007-03-28 2010-04-29 Laboratorios Del Dr. Esteve, S.A. Heterocyclyl-substituted-tetrahydro-naphthalen-amine derivatives, their preparation and use as medicaments
US8236845B2 (en) 2007-03-28 2012-08-07 Laboratorios Del Dr. Esteve, S.A. Heterocyclyl-substituted-tetrahydro-naphthalen-amine derivatives, their preparation and use as medicaments

Also Published As

Publication number Publication date
US7465750B2 (en) 2008-12-16
US20070259942A1 (en) 2007-11-08
US20090318504A1 (en) 2009-12-24

Similar Documents

Publication Publication Date Title
US7465750B2 (en) Use of GAL3 antagonist for treatment of depression and/or anxiety and compounds useful in such methods
US20030078271A1 (en) Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
US8198313B2 (en) Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
AU2008200385B2 (en) Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
US7220775B2 (en) Compound useful for the treatment of neuropathic pain
US7166635B2 (en) 3-imino-2-indolones for the treatment of depression and/or anxiety
AU2002247149A1 (en) Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
US20040110821A1 (en) GAL3 receptor antagonists for the treatment of affective disorders
WO2004014307A2 (en) Gal3 antagonists for the treatment of neuropathic pain
WO2004014376A1 (en) Gal3 receptor antagonists for the treatment of affective disorders
US6936607B2 (en) 2,4,6-Triaminopyrimidines for the treatment of depression and/or anxiety
AU2008200380A1 (en) Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
WO2004034967A2 (en) 2,4,6-triaminopyrimidines for the treatment of depression and/or anxiety

Legal Events

Date Code Title Description
AS Assignment

Owner name: H. LUNDBECK A/S, DENMARK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SYNAPTIC PHARMACEUTICAL CORPORATION;REEL/FRAME:015156/0196

Effective date: 20031231

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE